McGill, iSAEC Partner on TB Drug Reactions | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Montreal's McGill University will partner with the International Serious Adverse Events Consortium (iSAEC) to enable studies of the genetic basis of adverse reactions to Tuberculosis treatment.

The iSAEC's International Drug Induced Liver Injury Consortium (IDILIC) currently is recruiting patients with serious liver injuries from drugs and McGill is serving as the coordinating center for an international randomized trial for the treatment of latent TB.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.